(1) Dyonne T Hartong, Eliot L Berson, Thaddeus P Dryja, Retinitis pigmentosa, Lancet 2006; 368: 1795–809
(2) A. M. Joussen, V. Poulaki, M. L. Le et al., A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB Journal, vol. 18, no. 12, pp. 1450–1452, 2004.
(3) E. Buschini, A. Piras, R. Nuzzi, and A. Vercelli. Age related macular degeneration and drusen: neuroinflammation in the retina. Progress in Neurobiology, vol. 95, no. 1, pp. 14–25, 2011.
(4) J. P. Ehlers and S. Fekrat. Retinal vein occlusion: beyond the acute event.Survey of Ophthalmology, vol. 56, no. 4, pp. 281–299, 2011
(5) N. Yoshida, Y. Ikeda, S. Notomi et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology, vol. 120, no. 1, pp. 100–105, 2013
(6) Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009 Feb;118(1):69-77.
(7) P. Libby. Inflammation and cardiovascular disease mechanisms. The American Journal of Clinical Nutrition, vol.83, no. 2, pp. 456S–460S, 2006.
(8) S. Amor, F. Puentes, D. Baker, and P. Van Der Valk. Inflammation in neurodegenerative diseases. Immunology, vol.129, no. 2,pp. 154–169, 2010.
(9) C.K. Glass, K. Saijo, B. Winner, M.C. Marchetto, and F.H. Gage. Mechanisms underlying inflammation in neurodegeneration. Cell, vol.140,no.6,pp.918–934,2010.
(10) T. Wyss-Coray and L. Mucke. Inflammation in neurodegenerative disease—a double-edged sword. Neuron, vol.35,no.3,pp. 419–432, 2002.
(11) M. Y. Donath. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature Reviews Drug Discovery, vol.13, no. 6, pp. 465–476, 2014.
(12) K. Esposito and D. Giugliano. The metabolic syndrome and inflammation: association or causation?. Nutrition, Metabolism and Cardiovascular Diseases, vol.14, no. 5, pp.228–232,2004
(13) F.R.Balkwill and A. Mantovani, Cancer-related inflammation: common themes and therapeutic opportunities. Seminars in Cancer Biology,vol.22,no.1,pp.33–40,2012.
(14) Xie J, Van Hoecke L, Vandenbroucke RE. The Impact of Systemic Inflammation on Alzheimer's Disease Pathology. Front Immunol. 2022 Jan 6;12:796867.
(15) Zhang PF, Gao F. Neuroinflammation in Parkinson's disease: a meta-analysis of PET imaging studies. J Neurol. 2021 Nov 1. doi: 10.1007/s00415-021-10877-z.
(16) Guadagni V, Novelli E, Piano I, Gargini C, Strettoi E. Pharmacological approaches to retinitis pigmentosa: A laboratory perspective. Prog Retin Eye Res. 2015 Sep;48:62-81.
(17) Forrester JV, Reid DM, Campbell AM. Autoimmunity and retinitis pigmentosa. Semin Ophthalmol. 1987;2(2):81e8
(18) Newsome DA, Michels RG. Detection of lymphocytes in the vitreous gel of patients with retinitis pigmentosa. Am J Ophthalmol 1988;105:596–602.
(19) Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013 Jan;120(1):100-5.
(20) Olivares-González L, Velasco S, Campillo I, Rodrigo R. Retinal Inflammation, Cell Death and Inherited Retinal Dystrophies. Int J Mol Sci. 2021 Feb 20;22(4):2096.
(21) Ten Berge JC, Fazil Z, van den Born I, Wolfs RCW, Schreurs MWJ, Dik WA, Rothova A. Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract. Acta Ophthalmol. 2019 Mar;97(2):185-192.
(22) Okita A, Murakami Y, Shimokawa S, Funatsu J, Fujiwara K, Nakatake S, Koyanagi Y, Akiyama M, Takeda A, Hisatomi T, Ikeda Y, Sonoda KH. Changes of Serum Inflammatory Molecules and Their Relationships with Visual Function in Retinitis Pigmentosa. Invest Ophthalmol Vis Sci. 2020 Sep 1;61(11):30.
(23) Kaur G, Singh NK. The Role of Inflammation in Retinal Neurodegeneration and Degenerative Diseases. Int J Mol Sci. 2021 Dec 30;23(1):386.
(24) Niederkorn JY. Role of NKT cells in anterior chamber-associated immune deviation. Expert Rev Clin Immunol. 2009 Mar;5(2):137-144. doi: 10.1586/1744666X.5.2.137..
(25) Apte RS, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol. 1996 Apr 15;156(8):2667-73.
(26) Fischer K., Voelkl S., Heymann J., Przybylski G. K., Mondal K., Laumer M., et al. (2005). Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-) CD8- double-negative regulatory T cells. Blood 105 2828–2835
(27) Brandt D, Hedrich CM. TCRalphabeta(+)CD3(+)CD4(-)CD8(-) (double negative) T cells in autoimmunity.Autoimmun Rev. 2018 Apr;17(4):422-430.
(28) Voelkl S, Moore TV, Rehli M, Nishimura MI, Mackensen A, Fischer K. Characterization of MHC class-I restricted TCRαβ+ CD4−CD8− double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother CII 2009;58:709–18
(29) Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. Phenotypic and functional features of human Th17 cells J. Exp. Med. 2007 Aug 6;204(8):1849-61
(30) Cosmi L, Cimaz R, Maggi L, Santarlasci V, Capone M, et al. Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum. 2011 Aug;63(8):2504-15
(31) J. R. Sparrow, C. A. Parish, M. Hashimoto, and K. Nakanishi. A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. Investigative Ophthalmology and Visual Science, vol. 40, no. 12, pp. 2988–2995, 1999
(32) G. M. Holtkamp, A. Kijlstra, R. Peek, and A. F. de Vos, “Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes,” Progress in Retinal and Eye Research,vol.20,no.1,pp.29–48,2001
(33) D. M. Maurice, “Flow of water between aqueous and vitreous compartments in the rabbit eye,” American Journal ofPhysiology—Renal Fluid and Electrolyte Physiology,vol.252,no. 1,pp.F104–F108,1987
(34) S.A.Vinores,M.Kuchle,N.L.Derevjaniketal.,“Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization,” Histology and Histopathology,vol.10,no.4,pp.913–923,1995.
(35) R. B. Caldwell and B. J. McLaughlin, “Permeability of retinal pigment epithelial cell junctions in the dystrophic rat retina,” Experimental Eye Research,vol.36,no.3,pp.415–427,1983.
(36) Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., and Gage, F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918–934
(37) Arroba, A. I., and Valverde, A. M. (2017). Modulation of microglia in the retina: new insights into diabetic retinopathy. Acta Diabetol. 54, 527–533
(38) Cuenca, N., Fernandez-Sanchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., et al. (2014). Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog. Retin. Eye Res. 43, 17–75.
(39) Peng, B., Xiao, J., Wang, K., So, K. F., Tipoe, G. L., and Lin, B. (2014). Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. J. Neurosci. 34, 8139–8150.
(40) Zhao, L., Zabel, M. K., Wang, X., Ma, W., Shah, P., Fariss, R. N., et al. (2015). Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration. EMBO Mol. Med. 7, 1179–1197.
(41). Sohn, J. H., Kaplan, H. J., Suk, H. J., Bora, P. S., and Bora, N. S. (2000). Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest. Ophthalmol. Vis. Sci. 41, 3492–3502.
(42) Ten Berge JC, Fazil Z, van den Born I, Wolfs RCW, Schreurs MWJ, Dik WA, Rothova A. Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract. Acta Ophthalmol. 2018 Oct 8